Glenmark partners with BeiGene for launching innovative oncology medicines in India

Glenmark, a subsidiary of Glenmark Pharmaceuticals Ltd., entered into a partnership with BeiGene, a oncology company for marketing and distribution of Tislelizumab and Zanubrutinib in India.

According to the drug manufacturer, recent statistics indicate that India has the third highest number of cancer cases worldwide, with predictions suggesting this could reach 2.08 million cases by 2040 – a 57.5 per cent increase from 2020. 

Currently, cancer claims approximately 900,000 lives annually in India.

Tislelizumab is a novel anti-PD-1 monoclonal antibody approved by NMPA, EMA and FDA for the treatment of various types of cancers while, Zanubrutinib is a BTK inhibitor approved for the treatment of certain hematological malignancie